November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Helus Pharma Reports Psychedelic Drug Efficacy in Depression Trial Alongside Safety Concerns

🥗 Nutrition 2 min read 👁 8

A Phase 3 clinical trial indicates a psychedelic drug candidate significantly reduces major depression symptoms, though multiple serious adverse events prompt safety inquiries.

Helus Pharma Reports Psychedelic Drug Efficacy in Depression Trial Alongside Safety Concerns🥗Nutrition

Photo: statnews.com

Key points

  • Helus Pharma announced Phase 3 trial results for a psychedelic depression treatment.
  • Patients on the drug combined with standard antidepressants saw greater MADRS score reductions.
  • Serious adverse events raised questions regarding the treatment's safety profile.

A recent Phase 3 clinical trial evaluating a psychedelic drug candidate from Helus Pharma demonstrated significant symptom reduction in patients suffering from major depression, according to an announcement made by the company on Monday. Participants receiving the experimental therapy alongside standard antidepressants achieved a notable decrease in depressive symptoms, as measured by the MADRS rating scale, compared to those receiving a placebo.

Specifically, at the six-week mark, patients taking the active drug recorded an average reduction of 19.5 points on the scale, whereas the placebo cohort observed an 11.9-point drop. This therapeutic effect remained largely consistent through twelve weeks, with the treatment group maintaining a 16.9-point reduction against a 9.9-point decrease for the placebo group. The reported differences between both cohorts achieved statistical significance.

Despite the encouraging efficacy data, the study revealed a series of serious adverse events that have introduced questions regarding the overall safety profile of the intervention. Because the available findings are currently limited to company announcements without full peer-reviewed data, medical professionals emphasize the need for caution. Patients should always consult a qualified healthcare provider before making any personal medical decisions.

What to know

  • Treatment Context: The psychedelic compound was tested as an add-on therapy alongside standard antidepressant medications.
  • Trial Timeline: Results were measured at six and twelve weeks, showing sustained differences over the placebo group.
  • Safety Questions: Serious adverse events reported during the study highlight potential risks that require further evaluation.

Source statnews.com — statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.